Robert Toczycki, JD, MBA
bioboyscout.com
bioboyscout@gmail.com
847.227.7909
X: @BioBoyScout
On August 24, Arrowhead confirmed that the twelve-month results from SHASTA-3 and SHASTA-4 will be presented in Munich on Sunday, August 30. The topline came out on July 22 and the stock has already digested it. A scheduling announcement is not usually worth writing about.
This one is, because two of the details in it were decided by the European Society of Cardiology rather than by the company, and both say something about how the field intends to receive this trial.
The market already has the headline. Sunday is about validation, and validation is awarded by people who do not work for Arrowhead.
Hot Line is not the same as late-breaking
The presentation is in a Hot Line session, in the Munich Auditorium, Hall B3, at 17:30 on Sunday. The session is numbered nine, which is a scheduling detail and nothing more. The two words that carry weight are Hot Line.
Congresses run a great deal of late-breaking science. Hot Line is the tier above it, and it runs alongside a separate and larger late-breaking science track. By the society’s own July announcement, this year’s Hot Line program spans twelve sessions and 59 trials. Arrowhead’s slot is in the Munich Auditorium, Hall B3, which is where the Hot Line sessions are held.
The society describes the selection in its own words. Professor Tomasz Guzik, who chairs the ESC Congress Program Committee, said this year brought a record number of late-breaking submissions, and that the committee, in his phrase, rigorously selected the studies with the greatest scientific quality and potential clinical impact.
That is an editorial judgment made by cardiologists reviewing submitted data. It is not a slot a sponsor can buy. The inference worth drawing is bounded but real: a committee that saw a record volume of submissions looked at what Arrowhead sent and put it on the main stage.
The discussant is the tell
Every Hot Line presentation is followed by an assigned discussant whose job is to place the trial in context for the field and say plainly whether it should change what physicians do.
The discussant here is Borge Nordestgaard of Copenhagen University Hospital.
That name deserves explanation for anyone who does not follow lipid research. For decades he has led the Copenhagen population studies. Much of the modern evidence that high triglycerides actually cause heart disease, rather than simply appearing alongside it, comes from that work. When guideline committees debate whether triglycerides are worth treating, his data are central to the discussion.
The society did not assign a drug-development specialist to discuss this trial. It assigned the researcher whose work established that lowering triglycerides should matter in the first place.
That is a choice about framing. It signals ESC is treating SHASTA as evidence bearing on the triglyceride hypothesis itself, not simply as a registration trial for a rare disease drug.
The presenter reinforces the same reading. Gerald Watts of the University of Western Australia has chaired international guideline work on inherited lipid disorders. Between the presenter and the discussant, the society has put two people with real influence over treatment guidelines on the same stage.
Worth noting separately: Arrowhead has both of them on its investor webcast the following morning at 8:00 Eastern, alongside management, taking questions. That does not mean the company knows what Nordestgaard will say. He is independent, and the point of a discussant is that his assessment is his own. What it does mean is that whatever he says, favorable or critical, investors will hear it directly rather than filtered through a press release.
What actually lands on Sunday
The July topline reported median triglyceride reductions of 79 and 81 percent in the two studies, a 78 percent reduction in acute pancreatitis events across the broad severe hypertriglyceridemia population, and a 100 percent reduction in the highest-risk subgroup. Both trials met their primary endpoint and all pre-specified secondary endpoints.
Sunday brings the full dataset behind those numbers, across approximately 750 randomized patients, and the specific thing worth watching is durability.
The primary endpoint is percent change in fasting triglycerides from baseline to Month 12. Patients received four doses, one every three months. Which means the twelve-month measurement is taken at the end of the fourth dosing cycle, when drug effect is at its weakest point before the next injection would be due.
Any drug can look good at peak effect. A quarterly regimen is only real if the effect is still where it needs to be at the end of the quarter, four cycles into a year of treatment. That is what this endpoint measures, and it is the number that determines whether quarterly dosing is a convenience claim or a clinical fact.
Two things not in the release
Liver fat. James Hamilton, Arrowhead’s chief medical officer, confirmed in June that liver fat data would accompany these results, and the competitive stakes are specific.
The rival drug is olezarsen, from Ionis. Both drugs switch off the same gene, APOC3, but they do it with different molecular machinery. Olezarsen is an antisense oligonucleotide. Plozasiran is an siRNA. Same target, different tools.
That distinction is the whole question. Olezarsen showed liver fat increases of roughly 2 to 4 percent that grew with dose. Plozasiran showed none at its commercial dose in mid-stage testing. If the effect comes from suppressing APOC3 itself, both drugs should eventually show it. If it is a property of the antisense chemistry, only olezarsen will. Hamilton has pointed out that another antisense drug against a different lipid target showed the same pattern, which argues for chemistry, and he has also said openly that it may be a combination of both, and that if plozasiran shows a similar increase the two drugs are in the same boat.
Sunday, across 750 patients, is where that question gets a real answer.
Pancreatitis events, case by case. Triglyceride reduction is the primary endpoint. Pancreatitis is the outcome that matters to a patient, and it was pre-specified and pooled across both studies rather than found afterward. It is also the strongest clinical claim in the program, and it rests on a process most investors never see.
A patient in one of these trials turns up at a hospital with abdominal pain. Is that an attack of pancreatitis, or something else? The answer decides whether the event counts toward a pre-specified clinical outcome, and the sponsor cannot be the one deciding. An independent committee of physicians therefore reviews each suspected case and rules on it, separately from the sponsor. The process is called adjudication, and the committee that performs it exists precisely because the company has an interest in the answer.
The full presentation should show that process, the individual events, and the statistical range around a reduction reported as 100 percent in the highest-risk group, where the total number of events is necessarily small. A 100 percent reduction on four events is a different fact from a 100 percent reduction on forty.
The presentation nobody is watching
Monday morning at 9:00 Munich time, in a session titled Beyond statins: the next wave of lipid-lowering therapies, a Phase 3 trial of zodasiran in Chinese adolescents and adults with homozygous familial hypercholesterolemia will be presented by Zhuang Tian of Peking Union Medical College Hospital.
It appears in the ESC program under the designation vsa003 rather than any name Arrowhead uses in its own materials, which is one reason it is easy to overlook.
Homozygous familial hypercholesterolemia is genuinely ultra-rare, with global prevalence estimated between one in 250,000 and one in 360,000. It is hard to treat for a specific reason. Statins and most cholesterol drugs work through a receptor on the surface of liver cells. That receptor pulls cholesterol out of the blood. These patients inherited two broken copies of that receptor, so the usual drugs have little to work with. Zodasiran switches off a different gene entirely, one that does not depend on that receptor functioning.
This is a second late-stage asset presenting late-stage data at the same congress, in a named session, and it has attracted almost no attention. Which is the smaller version of the same point this note began with. The information that moves a company is not always the information the market is looking at, and it is frequently sitting in a program listing that nobody reads.
What this week is
Nothing presented in Munich is new information in the sense that the market has not seen the headline. The topline was July 22.
What happens on Sunday is different from a data release. It is the moment a trial stops being a company announcement and becomes part of the medical literature, presented by a guideline author, assessed in public by the researcher whose own work created the question the drug was built to answer.
Approvals determine whether a drug can be sold. Congresses like this one determine whether physicians believe it should be.
Chess used to settle unfinished games the same way. When a game ran past its time limit it was adjourned, and in many competitions the result could be decided by adjudication, in which an appointed master examined the position and ruled on what it was worth. Both players had already made every move. Nothing on the board could change. What remained was a judge, appointed by the federation rather than chosen by either side, declaring in public what the position was worth.
Arrowhead has made its moves. The data are locked and the topline is five weeks old. One set of adjudicators has already done its work, quietly, ruling case by case on which hospital admissions counted. Munich supplies a different kind, who rules in public on what the whole thing means. Neither side picked either of them.
Regulators have already said plozasiran can be sold in familial chylomicronemia syndrome, the rarest form of this disease. Sunday is about the much larger population behind it, and whether cardiologists believe the drug belongs there. ESC has chosen who tells them.
A Note on Supporting Independent Research
If this reaction note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.
For individual investors and readers
Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.
For family offices, investment funds, hedge funds, and research platforms
This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.
There is no obligation and no expectation. This is purely a thank you for work that meant something to you.
Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout
Thank you for reading, and for being part of a community that takes this thesis seriously.
— Robert Toczycki | BioBoyScout
Important Risks, Disclosures, & Disclaimers
The author, Robert Toczycki (aka BioBoyScout), certifies that:
all views expressed in this note accurately reflect his personal opinions about the topic discussed;
he was not compensated in any form for producing this note; and
he has not received and does not receive compensation from Arrowhead Pharmaceuticals.
This reaction note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions.
About the Author
Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.
Comments or questions: bioboyscout@gmail.com.
Copyright © 2026, BioBoyScout. All Rights Reserved.